Development of novel water-soluble phytostanol analogs: Disodium ascorbyl phytostanyl phosphates (FM-VP4): Preclinical pharmacology, pharmacokinetics and toxicology

Cardiovascular Drug Reviews

Volumn 21, Issue 3, 2003, Pages 151-168

  Ng, Agatha W K ^a   Lukic, Tatjana ^a   Pritchard, P Haydn ^a   Wasan, Kishor M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cholesterol; FM VP4; Hypolipemic drugs; Phytostanols

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN E; CHOLESTEROL; DISODIUM ASCORBYL PHYTOSTANYL PHOSPHATE; FM VP4; GLYCOPROTEIN P; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PHYTOSTANOL DERIVATIVE; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ATHEROSCLEROSIS; BODY WEIGHT; CELL STRAIN CACO 2; CHOLESTEROL METABOLISM; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; GERBIL; HUMAN; LIVER TOXICITY; MOUSE STRAIN; MUTAGENICITY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT STRAIN; REVIEW; TISSUE DISTRIBUTION; WEIGHT REDUCTION;

EID: 0141885372     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2003.tb00113.x     Document Type: Review

References (67)

1. Aviram M, Eias K. Dietary olive oil reduces low-density lipoprotein uptake by macrophages and decreases the susceptibility of the lipoprotein to undergo lipid peroxidation. Ann Nutr Metab 1993;37:75-84.
2. Becker M, Staab D, von Bergmann K. Treatment of severe familial hypercholesterolemia in childhood with sitosterol and sitostanol. J Pediatr 1993;122:292-296.
3. Becker M, Staab D, von Bergmann K. Long-term treatment of severe familial hypercholesterolemia in children: effects of sitosterol and bezafibrate. Pediatrics 1992;89:138-142.
4. Berge KE, Tian H, Graf GA, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000;290:1771-1775.
5. Bhadra S, Subbiah MT. Incorporation of liposomal phytosterols into human cells in culture: A potential in vitro model for investigating pathological effects of phytosterolemia. Biochem Med Met Biol 1991;46: 119-124.
6. Bodzioch M, Orso E, Klucken J, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 1999;22:347-351.
7. Borst P, Zelcer N, van Helvoort A. ABC transporters in lipid transport. Biochim Biophys Acta 2000;1486: 128-144.
8. Bradford RH, Shear CL, Chermnos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-49.
9. Brooks-Wilson A, Marcil M, Clee SM, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 1999;22:336-345.
10. Chiba T, Uematsu S, Sawamura F, et al. Effects of phosphatidycholine/phosphatidylethanolamine composition in cholesteryl ester-micellar substrates on neutral cholesterol esterase activity. Anal Biochem 1999; 268:238-244.
11. Connor WE. Dietary sterols: Their relationships to atherosclerosis. J Am Diet Assoc 1968;73:39-47.
12. Cohen DE, Angelico M, Carey MC. Quasielastic light scattering evidence for vesicular secretion of bilary lipids. Am J Physiol 1989;257:G1-G8.
13. Cohen BI, Mikami T, Ayyad N, Mikami Y, Mosbach EH. Dietary fat alters the distribution of cholesterol between vesicles and micelles in hamster bile. Lipids 1995;30:299-305.
14. Cullen P, Assmann G. High risk strategies for atherosclerosis. Clin Chim Acta 1999;286:31-45.
15. Debry P, Nash A, Neklason DW, Mether JE. Role of multidrug resistance P-glycoproteins in cholesterol esterification. J Biol Chem 1997;272:1026-1031.
16. Evans M, Rees A. The myotoxicity of statins. Curr Opin Lipidol 2002;13(4):415-420.
17. Field FJ, Born E, Satya NM. Effects of micellar sitosterol on cholesterol metabolism in Caco-2 cells. J Lipid Res 1997;38:348-360.
18. Gerson T, Shorland FB, Dunckley GG. The effects of sitosterol on the metabolism of choleserol and lipids in rats on a diet low in fat. Biochem J 1964;92:385-390.
19. Gylling H, Miettinen TA. Serum cholesterol and cholesterol and lipoprotein metabolism in hypercholesterolemic NIDDM patients before and during sitostanol ester-margarine treatment. Diabetologia 1994;37: 773-780.
20. Gylling H, Siimes MA, Miettinen TA. Sitostanol ester margarine in dietary treatment of children with familial hypercholesterolemia. J Lipid Res 1995;36:1807-1812.
21. Gylling H, Miettinen TA. Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin dependent diabetic men. J Lipid Res 1996;37: 1776-1785.
22. Gylling H, Radhakrishnan R, Miettinen TA. Reduction of serum choleserol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine: women and dietary sitostanol. Circulation 1997;96:4266-4231.
23. Gylling H, Miettinen TA. Cholesterol reduction by different plant stanol mixtures and with variable fat intake. Metabolism 1999;48:575-580.
24. Hallikainsen MA, Uusitupa MI. Effects of 2 low-fat stanol ester-containing margarines on serum cholesterol concentrations as part of a low-fat diet in hypercholesterolemic subjects. Am J Clin Nutr 1999;69:403-410.
25. Heinemann T, Axtmann G, von Bergmann K. Comparison of intestinal absorption of cholesterol with different plant sterols in man. Eur J Clin Invest 1993;23:827-831.
26. Hendriks HFJ, Weststrate JA, van Vliet T, Meijer GW. Spreads enriched with three different levels of vegetable oil sterols and the degree of cholesterol lowering in normocholesterolemic and mildly hypercholesterolemic subjects. Eur J Clin Nutr 1999;53:319-327.
27. Herbert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke and total mortality: An overview of randomized trials. JAMA 1997;278:1301-1307.
28. Hernandez M, Montenegro J, Steiner M, et al. Intestinal absorption of cholesterol is mediated by a saturable, inhibitable transporter. Biochim Biophys Acta 2000;1486:232-242.
29. Hirai K, Shimazu C, Takezoe R, Ozeki Y. Cholesterol, phytosterol and polyunsaturated fatty acid levels in 1982 and 1957 Japanese diets. J Nutr Sci Vitaminol 1986;32:363-372.
30. Jones PJH, Ntanios FY, Raeini-Sarjaz M, Vanstone CA. Cholesterol-lowering efficacy of a sitostanol-containing phytosterol mixture with a prudent diet in hyperlipidemic man. Am J Clin Nutr 1999;69:1144-1150.
31. Klein I, Sarkadi B, Varadi A. An inventory of the human ABC proteins. Biochim Biophys Acta 1999;1461: 237-262.
32. Konlande JE, Fisher H. Evidence for a nonabsorptive antihypercholesterolemic action of phytosterols in the chicken. J Nutr 1969;98:435-442.
33. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994;308:367-72.
34. Law MR. Lowering heart disease risk with cholesterol reduction: evidence from observational studies and clinical trials. Eur Heart J 1999;(Suppl 1):S3-S8.
35. Lawn RM, Wade DP, Garvin MR, et al. The Tangier disease gene product ABC1 control the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest 1999;104:R25-R31.
36. Lichtenberg D, Ragimova S, Bor A, et al. Stability of mixed micellar systems made by solubilizing phosphatidylcholine-cholesterol vesicles by bile salts. Hepatology 1990;12:149S-153S.
37. Luciani MF, Denizot F, Savary S, Mattei MG, Chimini G. Cloning of two novel ABC transporters mapping on human chromosome 9. Genomics 1994;21:150-159.
38. Luk AS, Kaler EW, Lee SP. Structural mechanisms of bile salt-induced growth of small unilamellar cholesterol-lecithin vesicles. Biochemistry 1997;36:5633-5644.
39. Lukic T, Wasan KM, Zamfir D, Moghadasian MH, Pritchard PH. The effect of FM-VP4 on blood cholesterol levels and the development of atherosclerosis in ApoE mice deficient mice. Metabolism 2003;52: 425-431.
40. McNeish J, Aiello RJ, Guyot D, et al. High-density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc Natl Acad Sci USA 2000;97: 4245-4250.
41. Metherall JE, Li H, Waugh K. Role of multidrug resistance P-glycoproteins in cholesterol biosynthesis. J Biochem 1996;271:2634-2640.
42. Moghadasian MH, McManus BM, Pritchard PH, Frohlich JJ. "Tail-Oil"-derived phytosterols reduce atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 1997;17:119-126.
43. M. H. Moghadasian. Effects of a "tall-oil"-derived phytosterol mixture on the development of atherosclerotic leisons in apo E-deficient mice. Ph.D. thesis. Vancouver, B.C., University of British Columbia; Faculty of Medicine, Department of Pathology and Laboratory Medicine, 1998.
44. Moghadasian MH, Godin DV, McManus BM, Frohlich JJ. Lack of regression of atherosclerotic leisions in phytosterol-treated Apo E-deficient mice. Life Sci 1999;64:1029-1036.
45. Moghadasian MH, Nguyen LB, Shefer S, et al. Histologic, hematologic, and biochemical characteristics of Apo E-deficient mice: Effects of dietary cholesterol and phytosterols. Lab Invest 1999;79:355-364.
46. Moghadasian MH, McManus BM, Godin DV, Rodrigues B, Frohlich JJ. Proatherogenic and antiatherogenic effects of probucol and phytosterols in apoE-deficient mice: Possible mechanisms of action. Circulation 1999;99:1733-1799.
47. Moghadasian MH, Frohlich JJ. Effects of dietary phytosterols on cholesterol metabolism and atherosclerosis: Clinical and experimental evidence. Am J Med 1999;107:588-594.
48. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25-60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15:678-682.
49. Peterson DW. Effect of soybean sterols in the diet on plasma and liver cholesterol in chicks. Proc Soc Biol Med 1951;78:143-147.
50. Ramaswamy M, Yau E, Wasan K, Boulanger KD, Li M, Pritchard PH. Influence of phytostanol phosphoryl ascorbate, FM-VP4, on pancreatic lipase activity and cholesterol accumulation within Caco-2 cells. J Pharmacol Pharm Sci 2002;5:29-38.
51. Repa JJ, Turley SD, Lobaccaro JM. Regulation of absorption and ABC-1 mediated efflux of cholesterol by RXR heterodimers. Science 2000;289:1524-1529.
52. Rust S, Rosier M, Funke H, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 1999;22:352-355.
53. Saunders DR, Wells MA. The cholesterol solubilizing capacity of lecithins in aqueous solutions of bile salt. Biochim Biophys Acta 1969;176:828-835.
54. Scandanavian Simvastatin Survival Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandanavian Simvastatin Survival Study. Lancet 1994;344:1383-1389.
55. Shepeherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study. N Engl J Med 1995;333:1301-1307.
56. Simons K, Ikonen E. How cells handle cholesterol. Science 2000;290:1721-1725.
57. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum cholesterol levels between 5.2 to 7.8 mmol/L plus two additional atherosclerosis risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Am J Cardiol 1993;72:1031-1037.
58. Tessner TG, Stenson WF. Overexpression of MDR1 in an intestinal cell line results in increased cholesterol uptake from micelles. Biochim Biophys Res Comm 2000;267:565-571.
59. Vanhanen HT, Kajander J, Lehtovirta H, Miettinen TA. Serum levels, absorption efficacy, fecal elimination and synthesis of cholesterol during increasing dosing of dietary sitostanol esters in hypercholesterolemic subjects. Clin Sci 1994;87:61-67.
60. Vanhanen HT, Blomqvist S, Ehnholm C, et al. Serum cholesterol, cholesterol precursors, and plant sterols in hypercholesterolemic subjects with different apo E phenotypes during dietary sitostanol ester treatment. J Lipid Res 1993;34:1535-1544.
61. Von Keutz E, Schluter G. Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor. Am J Cardiol 1998;82(4B):11J-17J.
62. Wasan KM, Najafi S, Peteherych KD, Pritchard PH. Effects of a novel hydrophilic phytostanol analog on plasma lipid concentrations in gerbils. J Pharm Sci 2001;90(11):1795-1799.
63. Wasan KM, Najafi S, Wong J, Kwong M. Assessing plasma lipid levels, body weight, and hepatic and renal toxicity following chronic oral administration of a water soluble phytostanol compound, FM-VP4, to gerbils. J Pharmacol Pharm Sci 2001;4:228-234.
64. Wasan KM, Peteherych KD, Najafi S. Assessing the plasma pharmacokinetics, tissue distribution, excretion and effects on cholesterol pharmacokinetics of a novel hydrophilic compound, FM-VP4 following administration to rats. J Pharmacol Pharm Sci 2001;4:207-216.
65. Wasan KM, Zamfir C, Pritchard PH, Pederson RA. Influence of Phytostanol Phosphoryl Ascorbate (FM-VP4) on insulin resistance, hyperglycermia, plasma lipid levels, and gastrointestinal absorption of exogenous cholesterol in zucker (fa/fa) fatty and lean rats. J Pharm Sci 2003;92:281-288.
66. Weisweller P, Heinemann V, Schwandt P. Serum lipoproteins and lecithin: cholesterol acyltransferase (LCAT) activity in hypercholesterolemic subjects given β-sitosterol. Int J Clin Pharmacol 1984;22: 204-206.
67. Young SC, Hui DY. Pancreatic lipase/co-lipase-mediated triacylglycerol hydrolysis is required for cholesterol transport from lipid emulsions to intestinal cells. Biochem J 1999;339:615-620.